TY - JOUR AU - Diefenbach, C. AU - Advani, R. PY - 2014 DA - 2014// TI - Customized targeted therapy in Hodgkin lymphoma: hype or hope? JO - Hematol Oncol Clin North Am VL - 28 UR - https://doi.org/10.1016/j.hoc.2013.10.004 DO - 10.1016/j.hoc.2013.10.004 ID - Diefenbach2014 ER - TY - JOUR AU - Gallamini, A. AU - Barrington, S. F. AU - Biggi, A. AU - Chauvie, S. AU - Kostakoglu, L. AU - Gregianin, M. PY - 2014 DA - 2014// TI - The predictive role of interim positron emission tomography on Hodgkin lymphoma treatment outcome is confirmed using the 5-point scale interpretation criteria JO - Haematologica VL - 99 UR - https://doi.org/10.3324/haematol.2013.103218 DO - 10.3324/haematol.2013.103218 ID - Gallamini2014 ER - TY - JOUR AU - Scott, D. W. AU - Steidl, C. PY - 2014 DA - 2014// TI - The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling JO - ASH Education Book VL - 1 ID - Scott2014 ER - TY - STD TI - Romano A, Vetro C, Caocci G, Greco M, Parrinello NL, Di Raimondo F, et al. Immunological deregulation in classic Hodgkin lymphoma. Mediterr J Hematol Infect Dis 2014; e2014039. doi:10.4084/MJHID.2014.039. ID - ref4 ER - TY - CHAP AU - Visser, L. AU - Van den Berg, A. AU - Poppema, S. AU - Diepstra, A. ED - Engert, A. ED - Horning, S. J. PY - 2011 DA - 2011// TI - Microenvironment, cross-talk, and immune escape mechanisms BT - Hodgkin lymphoma: a comprehensive update on diagnostics and clinics PB - Springer Verlag CY - Berlin UR - https://doi.org/10.1007/978-3-642-12780-9_4 DO - 10.1007/978-3-642-12780-9_4 ID - Visser2011 ER - TY - JOUR AU - Purdy, A. K. AU - Campbell, K. S. PY - 2009 DA - 2009// TI - Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR) JO - Cancer Biol The VL - 8 UR - https://doi.org/10.1158/1535-7163.MCT-09-0327 DO - 10.1158/1535-7163.MCT-09-0327 ID - Purdy2009 ER - TY - JOUR AU - Bashirova, A. A. AU - Martin, M. P. AU - McVicar, D. W. AU - Carrington, M. PY - 2006 DA - 2006// TI - The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense JO - Annu Rev Genomics Hum Genet VL - 7 UR - https://doi.org/10.1146/annurev.genom.7.080505.115726 DO - 10.1146/annurev.genom.7.080505.115726 ID - Bashirova2006 ER - TY - JOUR AU - Hsu, K. C. AU - Chida, S. AU - Geraghty, D. E. AU - Dupont, B. PY - 2002 DA - 2002// TI - The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism JO - Immunol Rev VL - 190 UR - https://doi.org/10.1034/j.1600-065X.2002.19004.x DO - 10.1034/j.1600-065X.2002.19004.x ID - Hsu2002 ER - TY - JOUR AU - Bontadini, A. AU - Testi, M. AU - Cuccia, M. C. AU - Martinetti, M. AU - Carcassi, C. AU - Chiesa, A. PY - 2006 DA - 2006// TI - Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population JO - J Transl Med VL - 4 UR - https://doi.org/10.1186/1479-5876-4-44 DO - 10.1186/1479-5876-4-44 ID - Bontadini2006 ER - TY - JOUR AU - Parham, P. AU - Moffett, A. PY - 2013 DA - 2013// TI - Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution JO - Nat Rev Immunol VL - 13 UR - https://doi.org/10.1038/nri3370 DO - 10.1038/nri3370 ID - Parham2013 ER - TY - JOUR AU - O’Connor, G. M. AU - Guinan, K. J. AU - Cunningham, R. T. AU - Middleton, D. AU - Parham, P. AU - Gardiner, C. M. PY - 2007 DA - 2007// TI - Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells JO - J Immunol VL - 178 UR - https://doi.org/10.4049/jimmunol.178.1.235 DO - 10.4049/jimmunol.178.1.235 ID - O’Connor2007 ER - TY - STD TI - Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201–14.ᅟ ID - ref12 ER - TY - JOUR AU - Marin, D. AU - Gabriel, I. H. AU - Ahmad, S. AU - Foroni, L. AU - De Lavallade, H. AU - Clark, R. PY - 2012 DA - 2012// TI - KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2011.180 DO - 10.1038/leu.2011.180 ID - Marin2012 ER - TY - JOUR AU - Bernal, M. AU - Garrido, P. AU - Jiménez, P. AU - Carretero, R. AU - Almagro, M. AU - López, P. PY - 2009 DA - 2009// TI - Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells JO - Hum Immunol VL - 70 UR - https://doi.org/10.1016/j.humimm.2009.07.004 DO - 10.1016/j.humimm.2009.07.004 ID - Bernal2009 ER - TY - JOUR AU - Karabon, L. AU - Jedynak, A. AU - Giebel, S. AU - Wołowiec, D. AU - Kielbinski, M. AU - Woszczyk, D. PY - 2011 DA - 2011// TI - KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic leukemia and the clinical course of disease JO - Tissue Antigens VL - 78 UR - https://doi.org/10.1111/j.1399-0039.2011.01721.x DO - 10.1111/j.1399-0039.2011.01721.x ID - Karabon2011 ER - TY - JOUR AU - Almalte, Z. AU - Samarani, S. AU - Iannello, A. AU - Debbeche, O. AU - Duval, M. AU - Infante-Rivard, C. PY - 2011 DA - 2011// TI - Novel associations between activating killer-cell immunoglobulin-like receptor genes and childhood leukemia JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2010-10-313791 DO - 10.1182/blood-2010-10-313791 ID - Almalte2011 ER - TY - JOUR AU - La Nasa, G. AU - Caocci, G. AU - Littera, R. AU - Atzeni, S. AU - Vacca, A. AU - Mulas, O. PY - 2013 DA - 2013// TI - Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients JO - Exp Hematol VL - 41 UR - https://doi.org/10.1016/j.exphem.2013.01.008 DO - 10.1016/j.exphem.2013.01.008 ID - La Nasa2013 ER - TY - JOUR AU - Besson, C. AU - Roetynck, S. AU - Williams, F. AU - Orsi, L. AU - Amiel, C. AU - Lependeven, C. PY - 2007 DA - 2007// TI - Association of killer cell immunoglobulin-like receptor genes with Hodgkin’s lymphoma in a familial study JO - PLoS One VL - 2 UR - https://doi.org/10.1371/journal.pone.0000406 DO - 10.1371/journal.pone.0000406 ID - Besson2007 ER - TY - JOUR AU - Hasenclever, D. AU - Diehl, V. PY - 1998 DA - 1998// TI - A prognostic score for advanced Hodgkin’s disease: international prognostic factors project on advanced Hodgkin’s disease JO - N Engl J Med VL - 339 UR - https://doi.org/10.1056/NEJM199811193392104 DO - 10.1056/NEJM199811193392104 ID - Hasenclever1998 ER - TY - JOUR AU - Gagne, K. AU - Brizard, G. AU - Gueglio, B. AU - Milpied, N. AU - Herry, P. AU - Bonneville, F. PY - 2002 DA - 2002// TI - Relevance of KIR gene polymorphisms in bone marrow transplantation outcome JO - Human Immunol VL - 63 UR - https://doi.org/10.1016/S0198-8859(02)00373-7 DO - 10.1016/S0198-8859(02)00373-7 ID - Gagne2002 ER - TY - JOUR AU - Yawata, M. AU - Yawata, N. AU - McQueen, K. L. AU - Cheng, N. W. AU - Guethlein, L. A. AU - Rajalingam, R. PY - 2002 DA - 2002// TI - Predominance of group A KIR haplotypes in Japanese associated with diverse NK cell repertoires of KIR expression JO - Immunogenetics VL - 54 UR - https://doi.org/10.1007/s00251-002-0497-x DO - 10.1007/s00251-002-0497-x ID - Yawata2002 ER - TY - JOUR AU - Middleton, D. AU - Gonzelez, F. PY - 2010 DA - 2010// TI - The extensive polymorphism of KIR genes JO - Immunology VL - 129 UR - https://doi.org/10.1111/j.1365-2567.2009.03208.x DO - 10.1111/j.1365-2567.2009.03208.x ID - Middleton2010 ER - TY - JOUR AU - Hay, A. E. AU - Meyer, R. M. PY - 2014 DA - 2014// TI - Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone JO - Hematol Oncol Clin North Am VL - 28 UR - https://doi.org/10.1016/j.hoc.2013.10.001 DO - 10.1016/j.hoc.2013.10.001 ID - Hay2014 ER - TY - JOUR AU - Tan, K. L. AU - Scott, D. W. AU - Hong, F. AU - Kahl, B. S. AU - Fisher, R. I. AU - Bartlett, N. L. PY - 2012 DA - 2012// TI - Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-04-421057 DO - 10.1182/blood-2012-04-421057 ID - Tan2012 ER - TY - JOUR AU - Scott, D. W. AU - Chan, F. C. AU - Hong, F. AU - Rogic, S. AU - Tan, K. L. AU - Meissner, B. PY - 2013 DA - 2013// TI - Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.43.4589 DO - 10.1200/JCO.2012.43.4589 ID - Scott2013 ER - TY - JOUR AU - Meyer, R. M. PY - 2013 DA - 2013// TI - EBV DNA: a Hodgkin lymphoma biomarker? JO - Blood VL - 121 UR - https://doi.org/10.1182/blood-2013-02-484451 DO - 10.1182/blood-2013-02-484451 ID - Meyer2013 ER - TY - JOUR AU - Knecht, H. AU - Kongruttanachok, N. AU - Sawan, B. AU - Brossard, J. AU - Prévost, S. AU - Turcotte, E. PY - 2012 DA - 2012// TI - Three dimensional telomere signatures of Hodgkin- and Reed-Sternberg cells at diagnosis identify patients with poor response to conventional chemotherapy JO - Transl Oncol VL - 5 UR - https://doi.org/10.1593/tlo.12142 DO - 10.1593/tlo.12142 ID - Knecht2012 ER - TY - JOUR AU - Benson, D. M. AU - Bakan, C. E. AU - Zhang, S. AU - Collins, S. M. AU - Liang, J. AU - Srivastava, S. PY - 2011 DA - 2011// TI - IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2011-06-360255 DO - 10.1182/blood-2011-06-360255 ID - Benson2011 ER - TY - JOUR AU - Kohrt, H. E. AU - Thielens, A. AU - Marabelle, A. AU - Sagiv-Barfi, I. AU - Sola, C. AU - Chanuc, F. PY - 2014 DA - 2014// TI - Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies JO - Blood VL - 123 UR - https://doi.org/10.1182/blood-2013-08-519199 DO - 10.1182/blood-2013-08-519199 ID - Kohrt2014 ER - TY - JOUR AU - Benson, D. M. AU - Hofmeister, C. C. AU - Padmanabhan, S. AU - Suvannasankha, A. AU - Jagannath, S. AU - Abonour, R. PY - 2012 DA - 2012// TI - A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma JO - Blood VL - 120 UR - https://doi.org/10.1182/blood-2012-06-438028 DO - 10.1182/blood-2012-06-438028 ID - Benson2012 ER - TY - JOUR AU - Murphy, W. J. AU - Parham, P. AU - Miller, J. S. PY - 2012 DA - 2012// TI - NK cells, from bench to clinic JO - Biol Blood Marrow Transplant VL - 18 UR - https://doi.org/10.1016/j.bbmt.2011.10.033 DO - 10.1016/j.bbmt.2011.10.033 ID - Murphy2012 ER -